The IC50 assay showed that the reduction in SOX9 expression significantly inhibited the viability of Linc00942‐overexpressing GBM cells and TMZ‐resistant GBM cells during TMZ treatment (Figure 5G; Figure S13B, Supporting Information). The gene discussed is SOX9; the disease is glioblastoma.